Sigyn Therapeutics, Inc. is a San Diego-based biotechnology company that specializes in developing innovative medical technologies to overcome therapeutic limitations in healthcare. Their focus is on optimizing the targeted delivery of therapeutic antibodies and cancer chemotherapies, as well as diminishing the toxicity of chemotherapy. With a vision to address pathogen-associated inflammatory disorders that are currently untreatable with drug therapies, Sigyn Therapy aims to target unmet needs in global health, including endotoxemia, drug-resistant infections, pneumonia, and sepsis.
Under the leadership of Chairman and CEO Jim Joyce, Sigyn Therapeutics is committed to strategic innovation, creating medical technologies that offer a competitive advantage within established industries. With a strong emphasis on research and development, the company aims to provide solutions that maximize the benefits of drug therapies and improve patient outcomes. As a pioneer in the field, Sigyn Therapeutics is poised to make a significant impact in the global market for therapeutic antibodies and cancer chemotherapies, which is projected to reach $250 billion by 2022.
Generated from the website